{"id":8201,"date":"2023-08-04T12:54:28","date_gmt":"2023-08-04T12:54:28","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=8201"},"modified":"2023-08-04T12:54:28","modified_gmt":"2023-08-04T12:54:28","slug":"tigit-cd155-cd112-cd226-network","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/tigit-cd155-cd112-cd226-network\/","title":{"rendered":"TIGIT \u2013 CD155 \u2013 CD112 \u2013 CD226 Network"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

T Cell Immunoreceptor with Immunoglobulin and ITIM domains (TIGIT) is an immune checkpoint receptor expressed on the surface of cytotoxic, memory and regulatory T cells (Tregs) as well as natural killer (NK) cells. TIGIT binds strongly to CD155 (PVR) and weakly to CD112 (Nectin-2). TIGIT suppresses immune activation on cytotoxic T cells and NK cells. In the normal immune system, the suppressive effect of TIGIT is counterbalanced by the immune-activating receptor CD226 (DNAM1), which competes with TIGIT to bind CD155 and CD112. The inhibitory signal provided by TIGIT overpowers the ability of CD226 to stimulate T cell activation. Tumour cells exploit the dominance of the inhibitory TIGIT pathway to avoid immune-mediated destruction. Recently, a high-affinity receptor of the ligand CD112\/Nectin-2, called CD112R\/PVRIG has been described and may become a new attractive cancer immunotherapy target.<\/p>\n\n\n\n

LIT:<\/strong>\u00a0\u00a0Identification of CD112R as a novel checkpoint for human T cells: Y. Zhu, et al.; J. Exp. Med.\u00a0213,<\/strong>\u00a0167 (2016) \u2022 Interaction of PVR\/PVRL2 with TIGIT\/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer: H. Stamm, et al.; Mamm. Genome\u00a029,<\/strong>\u00a0694 (2018)<\/p>\n\n\n\n

Biologically Active\u00a0TIGIT, CD112R and CD155 Proteins<\/strong>\u00a0\u00a0<\/p>\n\n\n\n

See all Biologically Active\u00a0TIGIT Proteins here:\u00a0AG-40B-0162<\/a> and ANC-556<\/a>.<\/p>\n\n\n\n

See all Biologically Active CD112R Proteins\u00a0here<\/a>.<\/p>\n\n\n\n

See all Biologically Active\u00a0CD155 Proteins\u00a0here<\/a>.<\/p>\n\n\n\n

VALIDATED\u00a0Antibodies for TIGIT, CD112R and CD155 Research<\/strong><\/p>\n\n\n\n

See all VALIDATED Antibodies for TIGIT Research here<\/a>.<\/p>\n\n\n\n

See all VALIDATED Antibodies for CD112R Research here<\/a>.<\/p>\n\n\n\n

See all VALIDATED Antibodies for CD155 Research here: ANC-255<\/a> and ANC-350<\/a>.<\/p>\n\n\n\n

\n
Back to T Cell Immune Checkpoints for Immuno-Oncology Research<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

Originally posted on\u00a0adipogen.com\/tigit-cd155-cd112-cd226-network\/<\/a><\/p>\n\n\n\n

Caltag Medsystems <\/a>is the distributor of Adipogen<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Tumour cells exploit the dominance of the inhibitory TIGIT pathway to avoid immune-mediated destruction.<\/p>\n","protected":false},"author":13,"featured_media":8211,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,1,637],"tags":[279,185,7,483],"class_list":["post-8201","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-general-information","category-t-cells","tag-adipogen","tag-antibodies","tag-cancer","tag-protein"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=8201"}],"version-history":[{"count":9,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8201\/revisions"}],"predecessor-version":[{"id":8212,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8201\/revisions\/8212"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/8211"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=8201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=8201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=8201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}